Services on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Revista Colombiana de Reumatología
Print version ISSN 0121-8123
Abstract
TUTA-QUINTERO, Eduardo; VEGA-CORREDOR, María Camila; PERDOMO-RODRIGUEZ, Laura Sofía and PIMENTEL, Juan. Colchicine, an old friend's perspectives for rheumatology in COVID-19: a scoping review. Rev.Colomb.Reumatol. [online]. 2022, vol.29, suppl.1, pp.35-47. Epub Feb 02, 2024. ISSN 0121-8123. https://doi.org/10.1016/j.rcreu.2021.02.002.
Introduction:
Colchicine is widely used to treat inflammatory diseases such as gout and Mediterranean fever. Due to its immunomodulatory capacity, it could play an important role in the treatment of COVID-19.
Objective:
To explore the current available medical evidence, published until 28 December 2020, regarding the efficacy and safety of colchicine in the treatment of patients with confirmed SARS-CoV-2 infection.
Material and methods:
Scoping review of the literature that included PubMed and Scopus. Records of clinical trials and publications with empirical data (observational and experimental studies) in English and Spanish were included.
Results:
A total of 33 clinical trials and 6 publications were found: prospective (n = 2) and retrospective (n = 2) cohort studies, randomised clinical trials (n = 1) and case-control studies (n = 1). The total number of participants in the trials is 46,324 individuals, 73% (24/33) of the studies are recruiting participants and 51% (17/33) are phase 3 studies. Conclusions: One clinical trial reports a decrease in prognostic inflammatory markers and length of hospital stay in SARS-CoV-2 infection. The ongoing clinical trials will clarify the efficacy and safety of colchicine for the management of patients with COVID-19.
Keywords : Systematic review; COVID-19; Colchicine; Rheumatology.
